EUVIMEDDescubrir EUVIMED
Crossref

Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction

Margaret R Jorgenson iD, Jillian L Descourouez iD, Christopher M Saddler, Jeannina A Smith, Jon S Odorico, John P Rice, Didier A Mandelbrot iD

Clinical Transplantation · 2023

DOI: 10.1111/ctr.15142 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Margaret R Jorgenson and 6 co-authors. Institution: Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA. Major MEDLINE topics: Cytomegalovirus Infections, Thrombocytopenia, Leukopenia. Cited 24 times so far (Crossref); 24 references.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Purpose

Valganciclovir (VGC) is the gold‐standard for cytomegalovirus (CMV) prophylaxis (PPX) after solid organ transplant (SOT). Letermovir (LTV) was recently approved in high‐risk kidney transplant and has reduced myelosuppressive toxicity. Conversion from VGC to LTV may be pursued in the setting of leukopenia. It is unknown if this strategy is effective.

Methods

Adult patients receiving abdominal SOT were included if converted from VGC to LTV between January 1, 2018 and January 31, 2023. Primary objective was to describe the impact of LTV conversion as measured by WBC recovery, mycophenolate modification, and use of GCSF, and prophylaxis efficacy assessed by course completion and breakthrough DNAemia. Secondary objective was to evaluate rates of post‐prophylaxis CMV.

Results

Seventy five SOT recipients met inclusion criteria. Mean change in WBC in response to LTV conversion by day 14 was +2.02 ± 2.52 k/uL. 75%(56/75) of the population did not require mycophenolate adjustment or had their dose increased after conversion. GCSF was required in 38.7%(29/75) prior to conversion; only 21.3%(16/75) of patients required GCSF after conversion. Early termination was uncommon, 14.7%(11/75) stopped due to lack of ongoing insurance approval, only one patient stopped due to adverse effects (1.3%). One patient had clinically significant breakthrough (1.3%) that was successfully managed with VGC. Incidence of post prophylaxis CMV was 40%.

Conclusion

Withholding of VGC with LTV conversion may improve leukopenia without need for additional supportive measures. Most importantly, this strategy avoided additional mycophenolate modifications. In our study, LTV was associated with low rates of breakthrough. Post‐prophylaxis CMV was similar to VGC prophylaxis.

Subjects

MeSH terms (MEDLINE)

Cytomegalovirus InfectionsThrombocytopeniaLeukopeniaAdultHumansValganciclovirCytomegalovirusAntiviral AgentsGanciclovirDrug TaperingImmunosuppressive AgentsAcetatesQuinazolines

Author keywords

cytomegaloviruspreventionrisk mitigationtoxicity

Substances

ValganciclovirAntiviral AgentsGanciclovirImmunosuppressive AgentsletermovirAcetatesQuinazolines

Authors and institutions

  • Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
  • Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
  • Depart of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.

ORCID profiles: Margaret R Jorgenson, Jillian L Descourouez, Didier A Mandelbrot

Cite

APA

Jorgenson, M. R., Descourouez, J. L., Saddler, C. M., Smith, J. A., Odorico, J. S., Rice, J. P., & Mandelbrot, D. A. (2023). Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction. Clinical Transplantation. https://doi.org/10.1111/ctr.15142

Vancouver

Jorgenson MR, Descourouez JL, Saddler CM, Smith JA, Odorico JS, Rice JP, et al. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction. Clinical Transplantation. 2023. doi:10.1111/ctr.15142

BibTeX
@article{Jorgenson2023,
  author = {Jorgenson, Margaret R and Descourouez, Jillian L and Saddler, Christopher M and Smith, Jeannina A and Odorico, Jon S and Rice, John P and Mandelbrot, Didier A},
  title = {Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.15142}
}
Start for free →